193 related articles for article (PubMed ID: 28031014)
1. CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies.
Sun C; Duan P; Luan C
Curr Drug Targets; 2017; 18(10):1142-1151. PubMed ID: 28031014
[TBL] [Abstract][Full Text] [Related]
2. The Epigenetic Landscape in the Treatment of Gynecologic Malignancies.
Eskander RN
Am Soc Clin Oncol Educ Book; 2018 May; 38():480-487. PubMed ID: 30231335
[TBL] [Abstract][Full Text] [Related]
3. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies.
Vegesna V; Takeuchi S; Hofmann WK; Ikezoe T; Tavor S; Krug U; Fermin AC; Heaney A; Miller CW; Koeffler HP
Leuk Res; 2002 May; 26(5):451-7. PubMed ID: 11916518
[TBL] [Abstract][Full Text] [Related]
4. Regulation of mouse chondrocyte differentiation by CCAAT/enhancer-binding proteins.
Okuma T; Hirata M; Yano F; Mori D; Kawaguchi H; Chung UI; Tanaka S; Saito T
Biomed Res; 2015; 36(1):21-9. PubMed ID: 25749148
[TBL] [Abstract][Full Text] [Related]
5. The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies.
Zivny J; Klener P; Pytlik R; Andera L
Curr Pharm Des; 2010 Jan; 16(1):11-33. PubMed ID: 20214615
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
7. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics in Hematological Malignancies.
Cruz-Rodriguez N; Combita AL; Zabaleta J
Methods Mol Biol; 2018; 1856():87-101. PubMed ID: 30178247
[TBL] [Abstract][Full Text] [Related]
9. The "Janus" Role of C/EBPs Family Members in Cancer Progression.
Tolomeo M; Grimaudo S
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560326
[TBL] [Abstract][Full Text] [Related]
10. Role of epigenetic changes in hematological malignancies.
Lehmann U; Brakensiek K; Kreipe H
Ann Hematol; 2004 Mar; 83(3):137-52. PubMed ID: 15064862
[TBL] [Abstract][Full Text] [Related]
11. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
Sashida G; Iwama A
Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
[TBL] [Abstract][Full Text] [Related]
12. DNA methyltransferases in hematologic malignancies.
Li KK; Luo LF; Shen Y; Xu J; Chen Z; Chen SJ
Semin Hematol; 2013 Jan; 50(1):48-60. PubMed ID: 23507483
[TBL] [Abstract][Full Text] [Related]
13. [A primer for epigenetics of hematological malignancies].
Nakajima H
Rinsho Ketsueki; 2016; 57(10):1835-1844. PubMed ID: 27725578
[TBL] [Abstract][Full Text] [Related]
14. [Epigenetic therapy for hematologic malignancies].
Kobayashi Y
Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
[TBL] [Abstract][Full Text] [Related]
15. A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer.
Halmos B; Bassères DS; Monti S; D'Aló F; Dayaram T; Ferenczi K; Wouters BJ; Huettner CS; Golub TR; Tenen DG
Cancer Res; 2004 Jun; 64(12):4137-47. PubMed ID: 15205324
[TBL] [Abstract][Full Text] [Related]
16. Autophagy regulation and its dual role in blood cancers: A novel target for therapeutic development (Review).
Jin S; Wei J; You L; Liu H; Qian W
Oncol Rep; 2018 Jun; 39(6):2473-2481. PubMed ID: 29658589
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.
Kinoshita T
Int J Hematol; 2004 Aug; 80(2):108-19. PubMed ID: 15481438
[TBL] [Abstract][Full Text] [Related]
18. EPHA3 as a novel therapeutic target in the hematological malignancies.
Keane N; Freeman C; Swords R; Giles FJ
Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
[TBL] [Abstract][Full Text] [Related]
19. Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment.
Misso G; Zarone MR; Grimaldi A; Di Martino MT; Lombardi A; Kawasaki H; Stiuso P; Tassone P; Tagliaferri P; Caraglia M
Curr Drug Targets; 2017; 18(1):35-55. PubMed ID: 27280795
[TBL] [Abstract][Full Text] [Related]
20. CCAAT/enhancer-binding proteins: structure, function and regulation.
Ramji DP; Foka P
Biochem J; 2002 Aug; 365(Pt 3):561-75. PubMed ID: 12006103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
